Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chi-BEAC Conditioning for Aggressive Lymphoma
NCT03629873Phase 2Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Feb 2018
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and peripheral T-cell lymphoma (PTCL), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Progression-free survival rate at 2 years. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT03629873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03629873.